Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

524
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
524
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

569
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
569
Controls in Experiments01:13

Controls in Experiments

14.4K
When conducting an experiment, it is crucial to have control to reduce bias and accurately measure the dependent variables. It also marks the results more reliable. Controls are elements in an experiment that have the same characteristics as the treatment groups but are not affected by the independent variable. By sorting these data into control and experimental conditions, the relationship between the dependent and independent variables can be drawn. A randomized experiment always includes a...
14.4K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

83
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
83
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

421
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
421
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

365
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
365

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological profiling of intravenous MP-04: sustained NAD<sup>+</sup> augmentation, immune modulation, and renal protection in preclinical models.

Frontiers in pharmacology·2026
Same author

Monocyte Dll4 Contributes to Systemic Inflammation in People Living With HIV.

Circulation research·2026
Same author

Research Limits on Knowledge of Benefit or Harm of Cannabis and Cannabinoids Use.

JAMA·2026
Same author

Monocytes Defined by Platelet Interactions and Oxidative Stress Signaling Underlie HIV-Associated Atherosclerosis.

Journal of the American Heart Association·2026
Same author

EcoHIV Infection Disrupts Dopamine and Serotonin Transporter Function, Altering Release Dynamics in C57BL/6J Mice.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology·2026
Same author

Regulation of eco-tropic human immunodeficiency virus type-1-infection by sterile alpha motif and histidine-aspartic domain containing protein-1 in a microglial cell line: a novel in vitro model for studying HIV infection and latency in microglia.

Journal of neurovirology·2025

Related Experiment Video

Updated: Nov 25, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.8K

COVID-19 and Cannabidiol (CBD).

Jag H Khalsa1, Greg Bunt, Sanjay B Maggirwar

  • 1US National Institute on Drug Abuse, NIH; Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse, NIH, Bethesda, Maryland (JHK); Samaritan Daytop Village Treatment Center and NYU Medical School, New York (GB); Microbiology, Immunology, and Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC (SBM); Institute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland (SK).

Journal of Addiction Medicine
|December 16, 2020
PubMed
Summary

Cannabidiol (CBD) is marketed for COVID-19 mental health issues, but evidence is lacking. This commentary highlights the absence of clinical trials proving CBD

More Related Videos

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

226
Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

556

Related Experiment Videos

Last Updated: Nov 25, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.8K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

226
Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

556

Area of Science:

  • Medical research
  • Neuroscience
  • Public Health

Background:

  • The COVID-19 pandemic caused significant health issues, including mental health challenges and substance use disorders.
  • Cannabis products, specifically cannabidiol (CBD), are being promoted as treatments for these post-COVID conditions.

Purpose of the Study:

  • To address the misconception that CBD effectively treats a wide range of COVID-19-associated mental health effects.
  • To emphasize the lack of robust clinical evidence supporting CBD's therapeutic use for anxiety, depression, or substance use disorders.

Main Methods:

  • This commentary critically evaluates the existing scientific literature.
  • It focuses on the absence of well-designed, double-blind, placebo-controlled clinical trials regarding CBD's efficacy.

Main Results:

  • There is a significant lack of sufficient unbiased clinical evidence to support CBD's use for treating COVID-19-related mental health conditions or substance use disorders.
  • Current evidence does not substantiate claims of CBD's antianxiety or antidepressant properties in this context.

Conclusions:

  • The widespread use of CBD for COVID-19-associated mental health issues is not supported by current scientific evidence.
  • Addiction physicians should guide patients requesting CBD prescriptions for these conditions, considering the lack of proven efficacy.